BioXpress Therapeutics

BioXpress Therapeutics SA is a premier provider of high-quality biologic APIs for unmet need indications.

Located in Geneva, Switzerland, BioXpress Therapeutics SA is a premier provider of high-quality biologic APIs (MAb and MAb-like biosimilars) for unmet need indications, such as cancer, inflammation and autoimmunity. BioXpress Therapeutics is focused on developing biosimilar monoclonal antibodies in many different countries. BioXpress Therapeutics currently has five programs in development, two of which are partnered with worldwide rights. See their pipeline for more information. BioXpress Therapeutics is activity seeking alliances with other biopharmaceutical companies and health organizations to accelerate the development of biosimilar therapeutics. They are already engaged in collaborations with partners from various countries and would like to hear from you. Please CONTACT US for pipeline partnership opportunities. The MAb-based drug market is one of the fastest growing categories of the biopharmaceuticals industry. These products are of high value for pharmaceutical industry, both in research as well as drug development activities. By 2011, biologics worth $18 billion USD in annual sales are expected to lose patent protection in developed countries and by 2018, over half of the approved MAbs will have lost patent protection, thus increasing the potential market size by a factor of at least 5 fold. The worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as a raft of branded drugs lose patent cover. Of those, monoclonal antibody therapeutics are forecasted to grow at a CAGR approaching 10% over the next five years, driven largely by positive results in the clinic. Cancers and immune-related inflammatory diseases will continue to be leading markets for MAbs during the five-year forecast period. 2010 was the first time in human history when nine human medicinal brands had sales exceeding $3 billion USD. Of these nine drugs, seven were biologics and of these, 6 were MAbs or MAb derivatives. BioXpress Therapeutics is rapidly advancing its biosimilars pipeline.